Accelerating all phases of the immuno-oncology drug development pipeline via immunosequencing
Adaptive Biotechnologies has built a robust immune medicine platform capable of aiding researchers and pharma partners across the immuno-oncology development spectrum—from early pre-clinical development through large scale registrational clinical trials. Adaptive’s core immunosequencing technology sequences T-cell receptors (TCR) and B-cell receptors (BCR) at high throughput, generating in-depth immune repertoire profiles. These rich datasets can be applied to answer key questions during drug development including determining the mechanism of action of a drug, identifying potential biomarkers of response, monitoring pharmacodynamics and kinetics, and predicting potential adverse events.
Additionally, Adaptive has developed technologies capable of pairing TCR alpha and beta chains, mapping TCRs to their cognate antigens, and characterizing the ability of TCRs to bind their target. This webinar will provide an overview of Adaptive’s suite of technologies and how attendees can use these tools to provide high-quality data to inform decision making and successfully advance their drug development projects.
This content applies to those across biotechnology research, pharmaceutical manufacturing and cell therapy development and/or manufacturing with roles spanning science and laboratory, research and business development.
